TeamDrive
RUS
Victor Stankevich

Victor Stankevich

Founding Partner, CEO

Телефоны:

+7 495 545-39-12

Send message

Viktor Stankevich is a Founding Partner of RMI Partners, a venture capital investment company in the area of innovative biopharmaceutical products.

Viktor has extensive experience of establishing and developing major projects in different sectors of the economy. In 2006-2012 Victor held different management positions at Mobile TeleSystems (MTS), one of Russia’s largest telecommunications companies. At MTS Group he was Director of External Resource Management and Control, and in 2010 was appointed Head of Procurement and a member of the Management Board.

Previously Victor spent more than 10 years (1996-2006) developing ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding. Victor was promoted from Head of Treasury to Deputy CEO. His “portfolio” of professional experience includes participation in the foundation of the Institute of Design Automation of the USSR Academy of Sciences, where he was in charge of the laboratory of artificial intelligence systems in design automation.

Victor graduated from Moscow Aviation Institute as a radio engineer, and from the Russian Foreign Trade Academy, specialising in international economic relations. Victor acquired an additional degree in 2002 from the Financial University under the Government of the Russian Federation, specialising in economics and finance.

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more